ANAB

AnaptysBioA

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$68.00

+32.7% vs current

Most likely

Base case

45%

Probability

Target price

$56.00

+9.2% vs current

B-

Bear case

30%

Probability

Target price

$38.00

-25.9% vs current

AI sentiment snapshot

Latest data as of 2026-04-21

AI commentary

Post-spin sentiment looks mixed rather than outright bullish. The key corporate event is now complete, which removes the 'will the separation happen' overhang [#8-K-2026-04-20], but the next step is proving that ANAB as a royalty-management company can convert Jemperli and imsidolimab economics into visible shareholder returns [#PR-2026-03-27]. Given the low-coverage setup, loose peer set, and deterministic score that still leans negative with only modest catalyst density, this reads as a cautious monitoring situation rather than a high-conviction rerating story.

RankAlpha Sentiment Codex - 2026-04-21

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-06-30catalystEarly post-spin capital allocation disclosuresHigh impact

The April 20, 2026 8-K confirms Anaptys completed the separation of First Tracks Biotherapeutics and retained the royalty-management business tied to Jemperli and imsidolimab. The March 27, 2026 company update said post-spin Anaptys would manage those financial collaborations with an initial approximately $140-$145 million in net cash and investments and a $100 million repurchase authorization, so the first disclosures showing actual buyback execution or other capital returns should be the first clean test of standalone ANAB valuation support [#8-K-2026-04-20] [#PR-2026-03-27].

2026-11-15eventGSK/Jemperli royalty cadence versus Sagard diversionHigh impact

Anaptys disclosed in its 2025 10-K that collaboration revenue was $234.6 million in 2025, and the March 3, 2026 results release said Jemperli 2025 sales exceeded $1.0 billion, triggering $50 million and $75 million commercial milestones while lifting 2025 Jemperli royalties to $96.0 million. However, the September 29, 2025 separation announcement also said Jemperli receivables remain payable to Sagard until the capped monetization threshold is met, so each update on partner sales and paydown timing materially affects what ultimately accrues to ANAB shareholders [#10-K-2026-03-03] [#PR-2026-03-03] [#PR-2025-09-29].

2027-12-31catalystCleaner pure-play royalty valuation after spin and toward de-encumbranceHigh impact

The completed spin-off leaves ANAB as a narrower royalty-management company holding rights to dostarlimab/Jemperli and imsidolimab royalties, while the separated biotech pipeline now sits at TRAX. Separation materials said Sagard's capped royalty monetization is expected to be fully paid down between mid-2027 and Q2 2028; if partner-led royalty cash flows remain healthy, investors may eventually underwrite a cleaner post-Sagard royalty stream and assign a more durable royalty-company multiple, but that rerating likely needs more than one quarter of evidence [#8-K-2026-04-20] [#PR-2025-09-29].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-04-21 • Updated nightlySource: Internal modelMethodology